COMMUNIQUÉS West-GlobeNewswire

NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study

06/09/2024 - 22:03

TORONTO and HAIFA, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”) is pleased to announce compelling new findings that [...]

Precipio Announces Employee Stock Option Plan Repricing

06/09/2024 - 22:00

Management lays out rationale and impact to shareholders below NEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the Company’s repricing of [...]

Fagron’s share buy-back program: Weekly update

06/09/2024 - 18:24

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 6 September 2024 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 2 September 2024 through 6 September 2024, Fagron [...]

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

06/09/2024 - 18:00

COPENHAGEN, Denmark, September 6, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial [...]

Findings From COBALT Trial, Including External Control Arm, Published in The American Journal of Gastroenterology

06/09/2024 - 16:30

Analysis compares results from confirmatory trial COBALT in PBC with real-world data from a pre-specified external control group utilizing the Komodo Health U.S. claims database Findings include statistically [...]

TOMI Environmental Solutions to Present at the H.C. Wainwright Annual Global Investment Conference

06/09/2024 - 16:08

FREDERICK, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization [...]

FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

06/09/2024 - 15:31

HOUSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of [...]

Alopexx Announces Investment from Biotech Consortia, Inc.

06/09/2024 - 15:00

Investment supports product development and commercialization of a potentially life-saving vaccine Cambridge, MA, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Alopexx, Inc., a clinical-stage biotechnology company focused on [...]

60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

06/09/2024 - 14:59

WASHINGTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today [...]

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

06/09/2024 - 14:30

New clinical efficacy and safety data for arimoclomol as a possible treatment for Niemann-Pick disease type C, including from long-term and real-world settings, demonstrate clinically meaningful reduction in disease [...]

Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences

06/09/2024 - 14:30

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today [...]

Safety Shot Announces Notice of Allowance for New Patent to Secure IP and Enforce Clinically Backed Claims

06/09/2024 - 14:30

New Patent is Added to the Company’s Portfolio of Formulations that Rapidly Reduce Blood Alcohol Content JUPITER, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Safety Shot , Inc. (Nasdaq: SHOT) (“Safety Shot” or “the Company [...]

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease

06/09/2024 - 14:00

Results from this trial are expected in 2025 SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral [...]

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

06/09/2024 - 14:00

DALLAS, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic [...]

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

06/09/2024 - 13:55

Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments TEL AVIV, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), [...]

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

06/09/2024 - 13:55

Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments Vancouver, Canada, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“ [...]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06/09/2024 - 13:30

PALO ALTO, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that [...]

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

06/09/2024 - 13:30

Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD) Topline data from the [...]

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

06/09/2024 - 13:30

NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]